- Home
- NEOV vs VTVT Comparison
NEOV vs VTVT Comparison
Compare NEOV & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | VTVT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 127.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NEOV | VTVT |
|---|---|---|
| Price | $5.01 | $33.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $55.25 |
| AVG Volume (30 Days) | ★ 1.3M | 21.8K |
| Earning Date | 02-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,486,857.00 | $17,000.00 |
| Revenue This Year | $148.14 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 486.23 | N/A |
| 52 Week Low | $1.80 | $13.96 |
| 52 Week High | $7.13 | $44.00 |
Technical Indicators
Market Signals| Indicator | NEOV | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 45.21 |
| Support Level | $4.44 | $32.50 |
| Resistance Level | $7.13 | $35.39 |
| Average True Range (ATR) | 0.77 | 3.05 |
| MACD | 0.12 | -0.74 |
| Stochastic Oscillator | 41.73 | 16.11 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.